Standard Biotools (LAB) Capital Expenditures Growth (3y) (2013 - 2026)
Standard Biotools (LAB) Capital Expenditures Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.45 Bn | 193.85 Bn | 7.27 Bn | -0.66% |
| 2 | Stryker | 127.62 Bn | 124.14 Bn | 4.50 Bn | 9.94% |
| 3 | Medtronic | 118.98 Bn | 109.76 Bn | 6.41 Bn | 8.89% |
| 4 | Boston Scientific | 73.41 Bn | 72.87 Bn | 3.85 Bn | 10.89% |
| 5 | Edwards Lifesciences | 51.89 Bn | 47.64 Bn | 1.35 Bn | 11.78% |
| 6 | Dexcom | 34.33 Bn | 32.38 Bn | 830.00 Mn | 12.81% |
| 7 | GE HealthCare Technologies | 33.87 Bn | 31.76 Bn | 2.18 Bn | 12.62% |
| 8 | Koninklijke Philips | 26.37 Bn | 23.05 Bn | 4.55 Bn | 19.51% |
| 9 | Steris | 23.04 Bn | 22.56 Bn | 684.20 Mn | 9.52% |
| 10 | Standard Biotools | 252.86 Mn | -223.86 Mn | 10.54 Mn | -25.68% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -25.68% |
| Mar 31, 2026 | -31.90% |
| Dec 31, 2025 | -1.75% |
| Sep 30, 2025 | -26.78% |
| Jun 30, 2025 | -93.03% |
| Mar 31, 2025 | 79.90% |
| Dec 31, 2024 | -102.62% |
| Sep 30, 2024 | -27.03% |
| Jun 30, 2024 | -27.45% |
| Mar 31, 2024 | -51.68% |
| Dec 31, 2023 | -31.18% |
| Sep 30, 2023 | 38.72% |
| Jun 30, 2023 | 9.34% |
| Mar 31, 2023 | -0.65% |
| Dec 31, 2022 | 14.73% |
| Sep 30, 2022 | -2.07% |
| Jun 30, 2022 | 30.82% |
| Mar 31, 2022 | 48.32% |
| Dec 31, 2021 | 192.40% |
| Sep 30, 2021 | 301.35% |